Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Nicotinic Modulation of the Cognitive Control System in Late-life Depression
Authors not listed
Vanderbilt University Medical Center · 2020
Abstract
Deficits in cognitive control are core features of late-life depression, contributing both to emotion dysregulation and problems with inhibiting irrelevant information, conflict detection, and working memory. Clinically characterized as executive dysfunction, these deficits are associated with poor response to antidepressants and higher levels of disability. Improvement of cognitive control network (CCN) dysfunction may benefit both mood and cognitive performance, however no current pharmacotherapy improves CCN deficits in LLD. Supported by pilot data, Investigators propose that nicotine acetylcholine receptor agonists enhance CCN function and resultantly improve mood and cognitive performance in late-life depression. The objective of this initial R61-phase trial is to first determine whether transdermal nicotine enhances CCN neural activity in an exposure-dependent fashion during an emotional response inhibition task (the emotional Stroop task). Investigator's approach for the R61 phase is to examine in 36 older adults with Major Depressive Disorder whether transdermal nicotine patches enhance CCN activity over 12 weeks as measured during fMRI with the emotional Stroop task while measuring nicotine and nicotine metabolite levels. Transdermal nicotine has a mechanism of action that is distinct from current antidepressants, potentially making it a potentially important antidepressant augmentation agent. If hypotheses are correct, as patches are commercially available, this approach could be rapidly moved into definitive studies and may have applicability to other psychiatric disorders characterized by CCN dysfunction.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-27 MST
Cite this
APA
Anonymous. (2020). Nicotinic Modulation of the Cognitive Control System in Late-life Depression. <em>Vanderbilt University Medical Center</em>. https://clinicaltrials.gov/study/NCT04433767
Vancouver
Anonymous. Nicotinic Modulation of the Cognitive Control System in Late-life Depression. Vanderbilt University Medical Center. 2020.
BibTeX
@misc{anon2020Nicoti,
title = {Nicotinic Modulation of the Cognitive Control System in Late-life Depression},
author = {Anonymous},
journal = {Vanderbilt University Medical Center},
year = {2020},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
biorxiv 2025
Preprint · CC-BY
Vascular contribution to cognitive impairment in heart failure with preserved ejection fraction: TRPV4 and KLF2 as key mediators of neurovascular dysfunction in the ZSF1 model
Journal of Neuroscience 2006
Open access · OA
Mitochondrial Trafficking to Synapses in Cultured Primary Cortical Neurons
biorxiv 2025
Preprint · CC-BY
Functional organizational principle evaluated by microstimulation in the cortical facial motor areas
Hasselt University 2019
Open access · US-GOV
Cause-effect Relationships Between Brain Networks and Bimanual Coordination in Older Adults
Journal of Neuroscience 2021
Open access · CC-BY
mTOR Attenuation with Rapamycin Reverses Neurovascular Uncoupling and Memory Deficits in Mice Modeling Alzheimer's Disease
University of Texas at Austin 2012
Open access · US-GOV